Qiagen, Seegene Ink MDx Development Agreement | GenomeWeb

NEW YORK (GenomeWeb) – Seegene will develop a menu of multiplex assay panels for Qiagen's QIAsymphony RGQ molecular diagnostics platform under a partnership announced by the companies today.

The first project under the partnership is to develop comprehensive panels to profile infectious diseases. Seegene's proprietary technologies for multiplexed real-time PCR analysis enable simultaneous amplification of up to 20 target genes per tube.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.